Direct thrombin inhibitor use during percutaneous coronary intervention

Spyros Kokolis; Luther T. Clark; Erdal Cavusoglu; Jonathan D. Marmur

doi:10.1097/01.fjc.0000154373.80659.38

Direct thrombin inhibitor use during percutaneous coronary intervention

Spyros Kokolis, Luther T. Clark, Erdal Cavusoglu, Jonathan D. Marmur

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Direct thrombin inhibitors (DTI) are emerging as alternative anticoagulants to unfractionated heparin and indirect thrombin inhibitors in patients undergoing percutaneous coronary intervention (PCI). We review the pharmacological properties of these newer antithrombotic agents and evaluate the clinical data demonstrating their use in patients undergoing PCI.

Original language	English
Pages (from-to)	270-279
Number of pages	10
Journal	Journal of Cardiovascular Pharmacology
Volume	45
Issue number	3
DOIs	https://doi.org/10.1097/01.fjc.0000154373.80659.38
State	Published - Mar 2005
Externally published	Yes

Keywords

Angioplasty
Bivalirudin
Percutaneous coronary intervention

Access to Document

10.1097/01.fjc.0000154373.80659.38

Cite this

@article{58a3adcea45148fa90cf468c08c07be3,

title = "Direct thrombin inhibitor use during percutaneous coronary intervention",

abstract = "Direct thrombin inhibitors (DTI) are emerging as alternative anticoagulants to unfractionated heparin and indirect thrombin inhibitors in patients undergoing percutaneous coronary intervention (PCI). We review the pharmacological properties of these newer antithrombotic agents and evaluate the clinical data demonstrating their use in patients undergoing PCI.",

keywords = "Angioplasty, Bivalirudin, Percutaneous coronary intervention",

author = "Spyros Kokolis and Clark, {Luther T.} and Erdal Cavusoglu and Marmur, {Jonathan D.}",

year = "2005",

month = mar,

doi = "10.1097/01.fjc.0000154373.80659.38",

language = "English",

volume = "45",

pages = "270--279",

journal = "Journal of Cardiovascular Pharmacology",

issn = "0160-2446",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "3",

}

TY - JOUR

T1 - Direct thrombin inhibitor use during percutaneous coronary intervention

AU - Kokolis, Spyros

AU - Clark, Luther T.

AU - Cavusoglu, Erdal

AU - Marmur, Jonathan D.

PY - 2005/3

Y1 - 2005/3

N2 - Direct thrombin inhibitors (DTI) are emerging as alternative anticoagulants to unfractionated heparin and indirect thrombin inhibitors in patients undergoing percutaneous coronary intervention (PCI). We review the pharmacological properties of these newer antithrombotic agents and evaluate the clinical data demonstrating their use in patients undergoing PCI.

AB - Direct thrombin inhibitors (DTI) are emerging as alternative anticoagulants to unfractionated heparin and indirect thrombin inhibitors in patients undergoing percutaneous coronary intervention (PCI). We review the pharmacological properties of these newer antithrombotic agents and evaluate the clinical data demonstrating their use in patients undergoing PCI.

KW - Angioplasty

KW - Bivalirudin

KW - Percutaneous coronary intervention

UR - http://www.scopus.com/inward/record.url?scp=14744269022&partnerID=8YFLogxK

U2 - 10.1097/01.fjc.0000154373.80659.38

DO - 10.1097/01.fjc.0000154373.80659.38

M3 - Review article

C2 - 15725953

AN - SCOPUS:14744269022

VL - 45

SP - 270

EP - 279

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 3

ER -

Direct thrombin inhibitor use during percutaneous coronary intervention

Abstract

Keywords

Access to Document

Fingerprint

Cite this